Mirum Pharmaceuticals, Inc. Insider Trading Activity
Mirum Pharmaceuticals chief executive Christopher Peetz reported routine equity activity involving company stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Mirum Pharmaceuticals chief executive Christopher Peetz reported routine equity activity involving company stock. On January 23, 2026, he exercised 12,500 restricted stock units, each converting into one share of common stock at an exercise price of $0, increasing his direct holdings to 176,233 shares.
On January 26, 2026, Peetz sold 6,831 shares of common stock at $96.192 per share, with the filing stating these shares were sold to cover tax withholding tied to the RSU vesting. After the sale, he directly owned 169,402 shares and also beneficially owned 187,500 shares indirectly through The Peetz Family Trust.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Common Stock | 6,831 | $96.192 | $657K |
| Exercise | Restricted Stock Units | 12,500 | $0.00 | $0.00 |
| Exercise | Common Stock | 12,500 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
Footnotes (3)
- F1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- F2. Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
- F3. 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date.
AI-generated analysis. How Rhea-AI works. Not financial advice.